FMD would not apply in case of no-deal Brexit

pharmafile | February 8, 2019 | News story | Medical Communications EU, FMD, UK, brexit, falsified medicines 

The Falsified Medicines Directive would be scrapped in the event of a no deal Brexit, the Association of the British Pharmaceutical Industry (ABPI) has warned. The scrapping of the EU legislation could put patients at risk.

According to the ABPI, the FMD, which comes into full effect on 9 February 2019, “will secure the supply chain of medicines, meaning that patients can be completely confident that the medicines they are taking are genuine and safe, whether that be antibiotics, statins or cancer medicines,” .

However pharmacies are still unsure as to whether the FMD will still apply in seven weeks’ time, as a no-deal Brexit would mean a UK revocation of the EU legislation.

Mike Thompson, Chief Executive of the ABPI, commented: “‘No deal’ is not in the interest of the NHS or its patients. Not being part of the safest medicines system in the world, one that the UK has helped design and build – and which provides protection against fake medicines – makes no sense. Being part of a system that keeps them safe is the minimum that UK patients should expect.”

However, the FMD would likely still be implemented in a scenario in which a deal is reached. As noted by the British Medical Association: “plans to implement the European Falsified Medicines Directive are expected to continue, despite the UK’s decision to leave the European Union.”

Louis Goss

Related Content


GSK’s RSV vaccine approved in EU for older adults

GSK has announced that the European Commission (EC) has authorised Arexvy, the company’s respiratory syncytial …


European Parliament shares goal to tackle antimicrobial resistance

The European Parliament has shared its recommendations for a “coordinated EU response to health threats …

Is the pharmaceutical sector prepared to face a titanium dioxide ban?

Dr Subhashis Chakraborty, head of Global Product Management, ACG Capsules In the wake of the …

Latest content